Hazelwood-based Mallinckrodt, the pharmaceuticals business of Covidien, announced a definitive agreement to acquire CNS Therapeutics Inc. for $100 million.
St. Paul, Minn.-based CNS Therapeutics Inc. is a privately held specialty pharmaceutical company that develops and commercializes products to treat neurological disorders and intractable chronic pain. It has one marketed product and many in development, Mallinckrodt said.